Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NoNO-42
- Development stage
- Phase 3
- Lead developer
- NoNO
- Modality
- Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
NoNO-42 is a peptide-based drug developed as an analog of nerinetide for the treatment of acute ischemic stroke. It acts as a PDZ domain inhibitor, specifically targeting postsynaptic density protein 95 (PSD95), which plays a key role in excitotoxic signaling pathways implicated in neuronal injury following stroke. By inhibiting PSD95-mediated interactions, NoNO-42 aims to reduce neural damage and improve outcomes after acute ischemic events. The drug is being developed by NoNO and has reached Phase II clinical trials for stroke. Its primary route of administration is intravenous infusion[2][3][5].
- Other names
- NoNO 42NoNO42NoNO-42nerinetide analog
02
Targets
DLG4 (Disks Large Homolog 4)
Beyond the preview
Go deeper on NoNO-42.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NoNO-42.